Document:

<PAGE>
                                                                   Exhibit 10.29

                                          [***] Confidential treatment requested

                        CONTRACT MANUFACTURING AGREEMENT

        This CONTRACT MANUFACTURING AGREEMENT (the "Agreement") is entered into
as of January 3, 2003 (the "Effective Date"), by and between ICOS Corporation
("ICOS"), a corporation organized and existing under the laws of the State of
Delaware and having its principal place of business at 22021 20/th/ Avenue S E,
Bothell, WA 98021 USA and Seattle Genetics, Inc. ("SGI"), a corporation
organized and existing under the laws of the State of Delaware and having its
principal place of business at 21823 30th Drive S.E., Bothell, WA 98021.

                                    RECITALS

         WHEREAS, ICOS is in the business of manufacturing and testing
pharmaceutical products; and

         WHEREAS, SGI is the proprietor of a certain DNA known as SGN-30
encoding a monoclonal antibody also known as SGN-30; and

         WHEREAS, ICOS has expertise in the development, evaluation and
production of monoclonal antibodies for therapeutic use using cell lines; and

         WHEREAS, subject to the terms and conditions set forth in this
Agreement, SGI wishes to have ICOS manufacture for SGI a pre-commercial
pharmaceutical Product (hereinafter defined); and

         WHEREAS, subject to the terms and conditions set forth in this
Agreement, ICOS wishes to manufacture Product for SGI.

         NOW, THEREFORE, the parties hereto, intending to be legally bound,
hereby agree as follows:

1.       Definitions

         For purposes of this Agreement, the following terms will have the
meanings set forth below:

         1.1 "Affiliates" means, with respect to any Person, another Person
that, directly or indirectly, controls, is controlled by or is under common
control with such Person. The term "control" means the possession, directly or
indirectly, of the power to direct or cause the direction of the management and
policies of a Person, whether through the ownership of voting securities, by
contract or otherwise. The direct or indirect ownership of at least fifty
percent (50%) or, if smaller, the maximum allowed by applicable law, of the
voting securities of a business entity or of an interest in the assets, profits
or earnings of a Person shall be deemed to constitute "control" of the Person.

                                       1

<PAGE>

                                          [***] Confidential treatment requested

         1.2  "Applicable Laws" means all ordinances, rules and regulations of
any kind whatsoever of any governmental or regulatory authority, including,
without limitation, the FDCA, that are applicable with respect to the context in
which the term is used.

         1.3  "Audit" means a [***] audit pursuant to which SGI or their
appointed representatives (such representatives to be reasonably acceptable to
ICOS) may (a) review the processes, procedures and documents of ICOS that are
used or maintained by ICOS to provide the Services, (b) assess of ICOS'
compliance with cGMP, Applicable Laws and quality assurance standards associated
with performing the Services, and (c) discuss any related issues with ICOS'
personnel and management involved in performing the Services.

         1.4  "Calendar Quarter" means the three-month period ending on March
31, June 30, September 30 or December 31. The initial Calendar Quarter will be
deemed to begin on the Effective Date and end on the first to occur of March 31,
June 30, September 30 or December 31 of such same year.

         1.5  "Calendar Year" means the twelve (12) month period ending on
December 31. The initial Calendar Year will be deemed to begin on the Effective
Date and end on December 31 of such same year.

         1.6  "Cell Line" means a [***] known as [***], which has been [***]
with a [***] containing certain SGI Materials as described in Appendix B, and
will be used to provide the Services herein. Any cell bank provided containing
the transfected cell line will always be subject to the license granted under
Appendix G herein.

         1.7  "cGMP" means Good Manufacturing Practices and General Biologics
Products Standards as promulgated under the FDCA.

         1.8  "Damages" means any and all [***] costs, losses, claims, actions,
liabilities, fines, penalties, costs and expenses, court costs, and [***] fees
and disbursements of counsel, consultants and expert witnesses incurred by a
party hereto (including interest which may be imposed in connection therewith).

         1.9  "FDA" means the United States Food and Drug Administration, any
comparable agency in any Foreign Jurisdiction, and any successor agency or
entity to any of the foregoing that may be established hereafter.

         1.10 "FDCA" means the Federal Food, Drug and Cosmetic Act (21 U.S.C.
(S).301 et seq.).

         1.11 "Foreign Jurisdiction" means any jurisdiction, not governed by the
United States or any political subdivision thereof, as agreed upon by the
parties.

         1.12 "ICOS Know-How" means unpatented and/or unpatentable technical
information, including ideas, concepts, inventions, discoveries, data, designs,
formulas, specifications, procedures for experiments and tests and other
protocols, results of experimentation and testing, fermentation and purification
techniques, and assay protocols owned by ICOS as of the Effective

                                       2

<PAGE>

                                          [***] Confidential treatment requested

Date which may be necessary for the performance of the Services. All ICOS
Know-How shall be Confidential Information of ICOS.

         1.13 "ICOS Patent Rights" mean the patent applications and patents
listed on Exhibit A to Appendix G hereto and all divisions, continuations,
continuations-in-part, and substitutions thereof; all foreign patent
applications corresponding to the preceding applications; and all U.S. and
foreign patents issuing on any of the preceding applications, including
extensions, reissues, and re-examinations.

         1.14 "IND" means an Investigation New Drug application or any
comparable application required by a Foreign Jurisdiction filed for the Product
by SGI with the FDA and all subsequent submissions, supplements or amendments
related thereto.

         1.15 "Manufacturing Specifications" means the specifications for
manufacturing the Product. Prior to the initiation of the first cGMP
manufacturing run, an Appendix C-1 signed by both parties setting forth the
initial Manufacturing Specifications shall be appended to this Agreement and
shall contain at a minimum a collection of documents containing certain
specifications, procedures, assay methods (QC Release Tests), personnel contacts
and any other information as may be needed and agreed by the parties relating to
the manufacture of Product by ICOS for SGI. This Appendix C-1 shall also contain
a statement to be agreed and acknowledged by ICOS and SGI that SGI adopts the
initial Manufacturing Specifications as its own specification in conformance
with Clause 6.7 herein. Any changes or additions to the Manufacturing
Specifications shall be made by the written agreement of ICOS and SGI.

         1.16 "NDA" means New Drug Application or any comparable application
required by a Foreign Jurisdiction filed for the Product by SGI with the FDA and
all subsequent submissions, supplements or amendments related thereto.

         1.17 "Person" means a natural person, a corporation, a partnership, a
trust, a joint venture, a limited liability company, any governmental authority
or any other entity or organization.

         1.18 "Price" means the price specified in Appendix E for the
Services.

         1.19 "Process" means the process for the production of the Product from
the Cell Line using the Manufacturing Specifications, including any improvements
thereto from time to time made as a result of the Services.

         1.20 "Product" means a monoclonal antibody derived from the Cell Line
manufactured by ICOS utilizing the Process, and incorporating technology
licensed to SGI from ICOS pursuant to the license agreement previously entered
into by the parties in the form set forth in Appendix G.

         1.21 "Product Specifications" means the product specifications listed
under the column "Acceptance Criteria" as listed in Appendix C.

                                       3

<PAGE>

                                          [***] Confidential treatment requested

         1.22 "Services" means all or any part of the services to be provided by
ICOS (or any permitted subcontractor) for the benefit of SGI pursuant to this
Agreement as further described in Appendix A.

         1.23 "SGI Patent Rights" means all patents and patent applications of
any kind throughout the world relating to the Process which from time to time
SGI is the owner of or is entitled to use.

         1.24 "SGI Information" means all confidential and proprietary technical
information not in the public domain relating to the Cell Line, the Process and
the Product, from time to time supplied by SGI to ICOS, or arranged by SGI to be
supplied by a third party (such as a prior manufacturer) to ICOS.

         1.25 "SGI Materials" means the Materials supplied by SGI to ICOS (if
any) and identified as such by Appendix B hereto.

         1.26 "SGI Technology" means the SGI Patent Rights and SGI Information
necessary to manufacture the Product.

         1.27 "SGI Tests" means the tests to be carried out on the Product
immediately following receipt of the Product by SGI, particulars of which are
set out in Appendix C.

         1.28 "Terms of Payment" means the terms of payment specified in
Section 5 and Appendix E.

         1.29 "Testing Laboratories" means any third party instructed by ICOS to
carry out tests on the Cell Line or the Product.

         1.30 "United States" means the fifty (50) states, the District of
Columbia and all of the territories of the United States of America.

2.       Supply by SGI

         2.1  Prior to or immediately following the Effective Date of this
Agreement SGI shall supply to ICOS SGI Information, together with full details
of any known hazards relating to SGI Materials with respect to their storage and
use. On review of this SGI Information and details SGI Materials shall be
provided to ICOS at ICOS's request when ICOS has satisfactorily determined that
SGI Materials do not pose a hazard to ICOS. SGI shall assist ICOS in making such
determination, but [***]. All property rights in the SGI Technology and/or SGI
Materials supplied to ICOS shall remain vested in SGI.

         2.2  SGI hereby grants ICOS the non-exclusive right to use the SGI
Materials and SGI Technology for the sole purpose of providing the Services.
ICOS hereby undertakes not to use SGI Materials or SGI Technology (or any part
thereof) for any other purpose.

                                       4

<PAGE>

                                          [***] Confidential treatment requested

           2.3 ICOS shall:

                 2.3.1 at all times use all reasonable efforts to keep the SGI
Materials secure and safe from loss or damage but in no case in a lesser manner
than ICOS stores its own material of similar nature;

                 2.3.2 not transfer to a third party any part of the SGI
Materials or the Product, except for the purpose of any tests at the Testing
Laboratories, provided, that, SGI is given prior notification or if SGI has
given prior written consent to such transfer; and

                 2.3.3 provide that such Testing Laboratories are subject to
obligations of confidence materially in the form of those obligations of
confidence imposed on ICOS under this Agreement.

           2.4   SGI warrants to ICOS that SGI is and shall at all times
throughout the duration of this Agreement remain entitled to supply the SGI
Materials and SGI Technology to ICOS for the performance of the Services.

           2.5   SGI warrants that the use by ICOS of SGI Materials and SGI
Technology for the Services will not infringe or is not alleged to infringe any
rights (including, without limitation, any intellectual or other proprietary
rights) vested in any third party.

           2.6   SGI shall indemnify, defend and hold harmless ICOS against any
loss, damage, costs and expenses of any nature (including court costs and legal
fees incurred by ICOS or ordered as payable by ICOS), whether or not foreseeable
or in the contemplation of ICOS or SGI, that ICOS may suffer as a result of any
third party claims, suits or actions arising out of or incidental to (a) any
breach of the warranties given in Clauses 2.4 and 2.5 above, (b) the
distribution or use of the Product, except to the extent such loss, damage,
costs and expenses are caused by ICOS's gross negligence or willful misconduct,
or (c) any claims by third parties alleging ICOS's use of the Cell Line, SGI
Materials, SGI Technology or the Manufacturing Specifications infringes any
rights (including, without limitation, any intellectual or other proprietary
rights) vested in any third party (whether or not SGI knew or should have known
about such alleged infringement) except to the extent ICOS infringes any rights
of any third parties by application of its production techniques while
performing the Services unless such application or production technique has been
developed as part of the Services. For the purposes of Clauses 2.6 and 2.7, the
term, production technique(s), is limited to all and any physical arrangement
and use of plant and equipment in the provision of Services.

           2.7   ICOS shall indemnify, defend and hold harmless SGI against any
loss, damage, costs and expenses of any nature (including court costs and legal
fees incurred by SGI or ordered as payable by SGI), whether or not foreseeable
or in the contemplation of SGI or ICOS, that SGI may suffer as a result of any
third party claims, suits or actions arising from ICOS's performance of the
Services except to the extent the loss or damage is a result of (a) SGI's gross
negligence or willful misconduct or (b) ICOS's use of an application or
production technique that has been developed as part of the Services for SGI or
is supplied by SGI. For the avoidance of doubt where ICOS's application or
production techniques, existed prior to the Effective Date, are not

                                       5

<PAGE>

                                          [***] Confidential treatment requested

developed as part of the Services hereto and whether or not included in the
Manufacturing Specifications, then they are covered by ICOS's undertaking of
indemnity and hold harmless.

         2.8 Notwithstanding the above, ICOS shall be at liberty to use SGI
Information as it sees fit in providing the Services subject to nondisclosure
pursuant to Section 7.

         2.9 The obligations of each party under this Section 2 shall survive
the termination of this Agreement for whatever reason.

3.       Provision of the Services

         3.1 ICOS shall diligently perform the Services as provided in Appendix
A and shall use all reasonable commercial efforts to achieve the estimated
schedules, specifications and amounts of Product. Furthermore, ICOS shall keep
SGI regularly informed of any changes to the estimated schedules for performance
of the Services and provide a monthly report, in a form agreed by the parties.

         3.2 With respect to all services provided by ICOS from time to time
that are agreed upon by the Parties but are listed on Appendix A as Additional
Services ("Additional Services"), SGI shall pay to ICOS an [***] of [***]. ICOS
will invoice SGI monthly for all Additional Services performed, with each such
invoice containing a reference to the services performed and the personnel used.
All such invoices will be payable under the terms described in Section 5.

         3.3 Except as set forth in Section 8.2, due to the unpredictable nature
of the biological processes involved in the Services, the schedules set down for
the performance of the Services (including, without limitation, the dates for
production and delivery of Product) set out in Appendix D are estimates only.

         3.4 The parties acknowledge that ICOS will ship each batch of cGMP
Product as soon as possible upon ICOS' completing the manufacture (including,
without limitation, the completion of all QA/QC tests) of such batch. Risk of
loss for Product shipped shall pass to SGI upon [***]; provided, however, that
[***]. Unless the parties agree otherwise, ICOS shall on behalf of and in
consultation with SGI (a) arrange for the transportation of Product, which shall
be made at the sole risk and expense of SGI and (b) pay shipping costs and be
reimbursed by SGI. In addition to reimbursing ICOS for the shipping costs, SGI
shall be responsible to ICOS for the payment of fees for Additional Services (as
set forth in Section 3.2) associated with arranging for the transportation of
the Product.

         3.5 Unless otherwise agreed, ICOS shall package and label Product for
delivery in accordance with its standard operating procedures. It shall be the
responsibility of SGI to provide prior written notice to ICOS of any special
packaging and labeling requirements for Product. All additional costs and
expenses (including reasonable profit) of whatever nature incurred by ICOS in
complying with such special requirements shall be charged to SGI in addition to
the Price.

         3.6 Upon completion of the Services, or as soon thereafter as can be
mutually agreed, ICOS will deliver to SGI a cell bank, generated by ICOS,
comprised of the Cell Line and used to provide the Services herein.

                                       6

<PAGE>

                                          [***] Confidential treatment requested

         3.7 Joint Communication on Manufacturing: ICOS and SGI shall
communicate and cooperate on a regular basis during the provision of Services
herein and in the event that the parties observe the need for a regular and
active committee, such body shall be established and meet regularly to discuss
and communicate the progress of the Services.

         3.8 ICOS shall provide SGI, at SGI's expense, with all documents SGI
reasonably requests regarding ICOS' performance of the Services and conducting
the Process of manufacturing the Product; provided, however, in the event that
SGI requests any documentation beyond that which ICOS is expressly required to
maintain pursuant to this Agreement, or which is otherwise already prepared by
ICOS and related to the Products or the Process, SGI shall be responsible to
ICOS for the payment of fees for Additional Services as set forth in Section
3.2.

         3.9 Once during this Agreement upon at least [***] ([***]) [***] prior
notice to ICOS, SGI shall have the right to have SGI representatives visit ICOS'
manufacturing facilities during normal business hours to conduct an Audit.
Notwithstanding the foregoing notice period, for purposes of confidentiality,
safety and to avoid the possibility of contamination, if a third party's product
is being produced during the time that SGI intends to conduct an Audit, such
Audit may be reasonably delayed upon prior written notice to SGI. The form,
participants and procedures of the Audit shall be subject to ICOS' reasonable
approval. When conducting an Audit, each of SGI's representatives will (a) be
subject to a nondisclosure obligation comparable in scope to Section 7, (b)
follow such security and facility access procedures as are reasonably designated
by ICOS, (c) be accompanied by an ICOS representative, (d) not enter areas of
any ICOS facility at times when any third party's products are being
manufactured to assure protection of ICOS' or third party confidential
information, and (e) use good faith efforts to avoid disrupting ICOS'
operations. In addition to an Audit, ICOS agrees to reasonably cooperate with
all regulatory authorities and shall submit to reasonable Product-specific
inspections by such authorities ("Regulatory Inspection"). Any Audits by SGI or
Regulatory Inspections in excess of one during this Agreement shall be [***]
([***]) [***] prior written notice. SGI shall pay to ICOS fees for all Audits by
SGI and Regulatory Inspections as Additional Services pursuant to Section 3.2.

4.       SGI Tests and Return Procedures

         4.1 Except where SGI has accepted ICOS Product tests and provided
written notice to ICOS of such acceptance, promptly following delivery of
Product or a sample of Product (if such sample is requested by SGI), SGI shall
carry out SGI Tests. If SGI Tests show that the Product fails to meet Product
Specifications due to ICOS failing to meet its obligations hereunder, SGI shall
give ICOS written notice thereof as soon as practicable but in no case later
than [***] ([***]) [***] from the date SGI takes delivery of the Product (or
sample of the Product, if applicable) and shall return such Product (or sample)
to ICOS's premises for further testing. In the absence of such written notice
Product shall be deemed to have been accepted by SGI as meeting Product
Specifications. If ICOS agrees that Product is Nonconforming Product, it shall
at SGI's discretion replace such Product at its own cost and expense, subject to
Section 4.3. "Nonconforming Product" means any Product that has been delivered
to SGI but fails to meet Product Specifications, and such failure is not due (in
whole or in part) to (a) acts or omissions of SGI, (b) [***], or (c) any third
party after delivery of such Product to SGI.

                                       7

<PAGE>

                                          [***] Confidential treatment requested

         FOR THE AVOIDANCE OF DOUBT, WHERE THE SPECIFICATION HAS NOT BEEN AGREED
BY THE PARTIES HERETO ICOS SHALL BE OBLIGED ONLY TO USE ITS REASONABLE
ENDEAVOURS TO PRODUCE PRODUCT THAT MEETS DRAFT PRODUCT SPECIFICATIONS.

         4.2 If there is any dispute concerning whether Product is Nonconforming
Product (as defined in Section 4.1), such dispute shall be referred for decision
to an independent expert (acting as an expert and not as an arbitrator) to be
appointed by agreement between ICOS and SGI.

         The costs of such independent expert shall be borne by the parties
equally; provided that the party that is determined to be incorrect in the
dispute shall be responsible for all such costs and shall indemnify the correct
party for its share of the costs incurred. The decision of such independent
expert shall be in writing and shall be binding on both ICOS and SGI.

         4.3 In the event Product is determined to be Nonconforming Product
(whether by agreement of ICOS pursuant to Section 4.1 or by an independent
expert pursuant to Section 4.2), ICOS shall replace such Product at its own cost
and expense and shall use commercially reasonable efforts to replace such
Product [***], provided that ICOS shall (a) [***] of such [***] within [***]
from the date the [***] and (b) [***] within [***] from the date ICOS [***] of
the [***]. If ICOS is [***] with the [***], then SGI shall [***] to a [***] of
the [***] of such [***].

         4.4 In the event that the parties hereto agree that a shipment or batch
of Product fails to meet Product Specifications as a result of ICOS failing to
meet its obligations hereunder, the entire shipment or batch of Product that
failed to meet Product Specifications shall either be returned to ICOS or
destroyed, at ICOS's option.

         4.5 The provisions of this Clause 4 shall be the sole remedies
available to SGI in respect of Product that fails to meet Product
Specifications.

5.       Price and Terms of Payment

         5.1    SGI shall pay the Price in accordance with the Terms of Payment
all as specified in Appendix E.

         5.2 Unless otherwise indicated in writing by ICOS, all prices and
charges are exclusive of state sales tax or of any other applicable taxes,
levies, duties and fees of whatever nature imposed by or under the authority of
any government or public authority, which shall be paid by SGI (other than taxes
on ICOS's income). All invoices are strictly net and payment must be made within
[***] ([***]) [***] of date of invoice. Payment shall be made without deduction,
deferment, set-off, lien or counterclaim of any nature.

         5.3 In default of payment on due date interest shall accrue on a day to
day basis with effect from the date which is [***] ([***]) [***] after the due
date for payment on any amount overdue at the [***] or the maximum rate
allowable under Washington law.

                                        8

<PAGE>

                                         [***] Confidential treatment requested

6.       Warranty and Limitation of Liability

         6.1 ICOS warrants that:

               6.1.1 the Services shall be performed in accordance with
Clause 3.1; and

               6.1.2 the Product when made available at ICOS' shipping docks
shall meet Product Specifications, except where the Product Specifications has
not been agreed between the parties hereto in which case ICOS shall be obliged
only to use its reasonable commercial efforts to produce Product that meets
draft Product Specifications.

               6.1.3 the Product delivered to SGI pursuant to this Agreement
shall conform to the Product Specifications and that such Product shall (i) be
free from defects in material and workmanship, (ii) be manufactured in
accordance with cGMP and Applicable Laws and (iii) be manufactured in accordance
with Appendix C hereof.

         6.2  Clause 6.1 is in lieu of all conditions, warranties and statements
in respect of the Services and/or the Product whether expressed or implied by
statute, custom of the trade or otherwise (including but without limitation any
such condition, warranty or statement relating to the description or quality of
the Product, its fitness for a particular purpose or use under any conditions
whether or not known to ICOS) and any such condition, warranty or statement is
hereby excluded. ICOS MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH
RESPECT TO THE PRODUCT. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING
WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A
PARTICULAR PURPOSE ARE HEREBY DISCLAIMED BY ICOS. IN NO EVENT SHALL ICOS BE
LIABLE FOR INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES.

         6.3  Without prejudice or modification to the terms of Clauses 6.1 and
6.2 the liability of ICOS to SGI, its permitted assigns and successors in
interest, for any loss suffered by SGI or its permitted assigns and successors
in interest, arising as a direct result of a breach of this Agreement, or of any
other liability, including without limitation, misrepresentation and negligence
(whether active, passive or imputed), arising out of this Agreement and Services
provided thereunder, including without limitation the production and/or supply
of the Product, shall be limited to the payment of damages which shall not
exceed in US Dollars THE PRICE FOR SERVICES PAID BY SGI UNDER THE AGREEMENT;
provided, however, if and to the extent such damages are caused by ICOS's
willful or intentional breach of this Agreement or willful or intentional
misconduct in the performance of the Services, then the damage limitation in
this Clause 6.3 shall not apply.

         6.4  ICOS shall in no event be liable for the following loss or damage
howsoever caused (even if foreseeable or in the contemplation of ICOS or SGI):

               6.4.1 loss of profits, business or revenue suffered by SGI or
any other person who may be subrogated to, or assigned rights in the loss or
damage; or

               6.4.2 special, indirect or consequential loss, whether suffered
by SGI or any other person.

                                       9

<PAGE>

                                          [***] Confidential treatment requested

         6.5 SGI shall indemnify, defend and hold harmless and maintain ICOS
indemnified and held harmless against all Damages in respect of:

               6.5.1 any product liability in respect of Product, except for
ICOS's obligations to indemnify in Clause 2.7 above; and

               6.5.2 any negligent (active, passive or imputed), gross
negligence or intentional act or omission of SGI in relation to the use,
processing, storage or sale of the Product.

         6.6  SGI represents and warrants that unless already expressly agreed
in a written and executed document immediately prior to the initiation of the
first cGMP manufacturing run, SGI will adopt the initial Manufacturing
Specifications as its own specification. Any changes or additions to the
Manufacturing Specifications shall be made with the written approval of SGI.

         6.7  The obligations of SGI under this Section 6 shall survive the
termination for whatever reason of this Agreement.

7.       Confidentiality

         7.1  Each party agrees to keep the other party's Confidential
Information (as defined in Clause 7.3) strictly confidential and to respect the
other's proprietary rights therein and not at any time for any reason whatsoever
to disclose or use the other party's Confidential Information for any purpose
other than as expressly provided herein.

         7.2  SGI and ICOS shall each ensure that all their respective
employees, consultants and contractors having access to confidential ICOS
Know-How or confidential SGI Materials or SGI Technology shall be subject to the
same obligations of confidence as the principals pursuant to Clause 7.1 and
shall be subject to written confidentiality agreements in support of such
obligations.

         7.3  For purposes of this Agreement, "Confidential Information" means
any business or technical information, trade secrets, know-how, techniques, data
or other information, disclosed by the disclosing party to the receiving party
in writing or that is disclosed orally and confirmed in writing as confidential
within [***] following such disclosure. The parties agree that SGI `s
Confidential Information includes, without limitation, the SGI Materials and SGI
Technology. The parties further agree that ICOS's Confidential Information
includes, without limitation, ICOS Know-How.

         7.4  The obligations of confidence referred to in this Section 7 shall
not extend to any Confidential Information that:

               7.4.1 is or becomes generally available to the public
otherwise than by reason of a breach by the recipient party of the provisions of
this Section 7;

               7.4.2 is lawfully known to the recipient party prior to its
receipt from the other;

                                       10

<PAGE>

                                          [***] Confidential treatment requested

               7.4.3 is subsequently disclosed to the recipient party without
being made subject to an obligation of confidence by a third party that does not
have a prior obligation of confidence to SGI or ICOS, as the case may be; or

               7.4.4 which may be required to be disclosed under any statutory,
regulatory or similar legislative requirement, subject to the imposition of
obligations of confidentiality to the extent allowed and provided further that
each party shall, unless prohibited by law, use reasonable efforts to notify the
other party of such compelled disclosure prior to such disclosure in order to
seek injunctive or any other relief provided in law or equity; or

               7.4.5 is independently developed by the recipient party
without reliance on the Confidential Information of the disclosing party as
shown by its written records.

         7.5  SGI acknowledges that:

               7.5.1 ICOS Know-How and ICOS Patent Rights are vested in
ICOS; and

               7.5.2 Except as expressly provided herein, SGI shall not at any
time have any right, title, license or interest in or to ICOS Know-How, ICOS
Patent Rights or any other intellectual property rights relating to the Process
which are vested in ICOS or to which ICOS is otherwise entitled.

         7.6  ICOS acknowledges that:

               7.6.1 except as provided herein, all right, title and interest in
the SGI Materials and SGI Technology are vested in SGI; and

               7.6.2 except as provided herein, ICOS shall not at any time
have any right, title, license or interest in or to SGI Technology or any other
intellectual property rights vested in SGI or to which SGI is entitled.

         7.7  The obligations of ICOS and SGI under this Section 7 shall survive
the termination of this Agreement for whatever reason.

8.       Termination

         8.1 If it becomes apparent to either ICOS or SGI at any stage in the
provision of the Services that it will not be possible to complete the Services
for [***] reasons due solely to any [***] that are [***] from those [***] (the
"[***]"), the parties will use good faith commercially reasonable efforts for up
to a [***] ([***]) [***] period to mutually resolve such problems. If, after
using the foregoing level of effort, the parties are unable to resolve such
problems within the [***] ([***]) [***] period, ICOS and SGI shall each have the
right to terminate this Agreement. In the event of such termination, SGI shall
pay to ICOS a termination sum equal to the [***]; provided, however, that in the
event ICOS is [***] the [***], ICOS and SGI shall [***] a [***], with
consideration of the [***] in [***].

         8.2 If, [***], it becomes apparent to either ICOS or SGI at any stage
in the provision of the Services that it will not be possible to complete the
Services (including delivery of all [***]

                                       11

<PAGE>

                                          [***] Confidential treatment requested

cGMP clinical production runs of Product in compliance with this Agreement by
[***]) based on [***] reasons other than those described in Section 8.1, the
parties will use good faith commercially reasonable efforts for up to a [***]
([***]) [***] period to mutually determine the cause of the problems so as to
permit ICOS to manufacture and deliver Product that conforms with the Product
Specifications (even if the mutual determination and subsequent delivery of
conforming Product [***]). If, after using the foregoing level of effort, the
parties are unable to mutually determine the cause of such problems within the
[***] ([***]) [***] period, ICOS and SGI shall each have the right to terminate
this Agreement. In the event of such termination, SGI shall pay to ICOS a
termination sum calculated by reference to [***] (including a [***] (as
demonstrated by [***] in so far as they are applicable) of the [***] for any
[***] which is [***]) and all [***] in [***], including the [***] under the
Agreement, such termination sum not to exceed the [***]; provided, however, that
if the termination sum is less than the amount of any advance payments made by
SGI against the performance of the Services, ICOS will refund the residue of
such advance payments to SGI.

         8.3 SGI shall be entitled to terminate this Agreement at any time for
any reason by [***] ([***]) [***] notice to ICOS in writing provided that for
any termination under this Section 8.3 SGI shall be responsible to pay to ICOS
the termination sum described in Section 8.1 (subject to any potential refund as
described therein).

         8.4 ICOS and SGI may each terminate this Agreement by notice in writing
to the other upon the occurrence of any of the following events:

               8.4.1 if the other commits a breach of this Agreement which
(in the case of a breach capable of remedy) is not remedied within [***] ([***])
[***] of the receipt by the other of written notice identifying the breach with
specificity and requiring its remedy; provided, however, if the breach is as a
result of nonpayment of any amounts owing, the breaching party must remedy the
breach within [***] ([***]) [***] after receiving such written notice; or

               8.4.2 if the other ceases for any reason to carry on business
or convenes a meeting of its creditors or has a receiver or manager appointed in
respect of all or any part of its assets or is the subject of an application for
an administration order or of any proposal for a voluntary arrangement or enters
into liquidation (whether compulsorily or voluntarily) or undergoes any
analogous act or proceedings under foreign law; provided, however, either party
may merge with or into another equity pursuant to which the obligations of this
Agreement will be assumed or effect the sale of all its assets or substantially
all of its assets pursuant to which the acquiring party will assume such party's
obligations under this Agreement without notice to or waiver by the other party.

               If this Agreement is terminated due to SGI's breach (which SGI
fails to cure as described in Section 8.4.1), then SGI shall be responsible to
pay to ICOS the termination sum described in Section 8.1 (subject to [***] as
described therein).

         8.5 Unless terminated earlier pursuant to Sections 8.1 through 8.4,
this Agreement shall terminate upon SGI's acceptance of [***] cGMP clinical
production runs of Product in compliance with this Agreement.

                                       12

<PAGE>

                                          [***] Confidential treatment requested

         8.6 Upon the termination of this Agreement for whatever reason:

              8.6.1 ICOS shall promptly return all SGI Information to SGI and
shall dispose of or return to SGI all SGI Materials, and any materials
therefrom, as directed by SGI;

              8.6.2 SGI shall promptly return to ICOS all ICOS Know-How it has
received from ICOS except as set forth in Section 8.6.3 below;

              8.6.3 If, after expiration or termination of this Agreement,
SGI determines to manufacture the Product, or have the Product manufactured by a
third party, ICOS will supply to SGI and/or SGI's third party designee all
reasonably available information and data relating to the Process and the
Manufacturing Specifications. In addition, ICOS will [***] and/or its [***] a
[***] to all [***], if any, [***] to [***] or its [***] to [***] in accordance
with the [***]. ICOS [***] that SGI will not [***] to the [***], other than the
[***] previously [***], to [***] or its [***] to [***] in accordance with the
[***]. Except as permitted by the foregoing, following [***] shall not [***] the
[***].

              8.6.4 ICOS may thereafter use or exploit the ICOS Know-How and
ICOS Patent Rights in any way whatsoever without restriction; and

              8.6.5 ICOS and SGI shall do all such acts and things and shall
sign and execute all such deeds and documents as the other may reasonably
require to evidence compliance with this Clause 8.6.

              8.6.6 The license agreement previously entered into by the
parties in the form attached hereto as Appendix G shall remain in full force and
effect regardless of any termination of this Agreement.

         8.7 Termination of this Agreement for whatever reason shall not affect
the accrued rights of either ICOS or SGI arising under or out of this Agreement
and Sections 2, 3.8, 3.9, 6, 7, and 8 and any definitions in Section 1 required
to interpret such surviving provisions, and all provisions which are expressly
to survive this Agreement or have a continuing obligation shall remain in full
force and effect.

9.       Force Majeure

         Neither ICOS nor SGI shall be deemed to be in default nor be liable for
loss, damage, or delay in performance, when and to the extent due to causes
beyond its reasonable control or from fire, strike, labor difficulties,
insurrection or riot, embargo, or inability to obtain materials from usual
sources, or any other unforeseeable cause or causes beyond the reasonable
control and without the fault or negligence of the party so affected, or from
defects or delays in the performance of its suppliers or subcontractors due to
any of the foregoing enumerated causes. If ICOS is prevented or delayed in the
performance of any of its obligations under this Agreement by Force Majeure and
shall give written notice thereof to SGI specifying the matters constituting
Force Majeure together with such evidence as ICOS reasonably can give and
specifying the period for which it is estimated that such prevention or delay
will continue, ICOS shall be excused from the performance or the punctual
performance of such obligations as the case may be from the date of such notice
for so long as such cause of prevention or delay shall continue,

                                       13

<PAGE>

                                          [***] Confidential treatment requested

provided that within [***] ([***]) [***] from the date of such notice, ICOS
shall provide SGI with written notice of the anticipated date of resumption of
performance. In the event that the anticipated date of such resumption is
greater than [***] ([***]) [***] from the date of the original notice, SGI may
terminate this Agreement under Section 8.4.1 hereof.

10.      Governing Law, Jurisdiction and Enforceability

         10.1 This Agreement shall be governed and interpreted, and all rights
and obligations of the parties shall be determined, in accordance with the laws
of the State of Washington and the United States of America without regards to
principles of conflicts of law.

         10.2 No failure or delay on the part of either ICOS or SGI to exercise
or enforce any rights conferred on it by this Agreement shall be construed or
operate as a waiver thereof nor shall any single or partial exercise of any
right, power or privilege or further exercise thereof operate so as to bar the
exercise or enforcement thereof at any time or times thereafter of any other
right.

         10.3 The illegality or invalidity of any provision (or any part
thereof) of this Agreement shall not affect the legality, validity or
enforceability of the remainder of its provisions or the other parts of such
provision as the case may be and this Agreement shall continue in full force and
effect without such provision.

11.      Miscellaneous

         11.1 Assignment. Neither party shall be entitled to assign, or in any
way transfer the benefit and/or the duties of this Agreement without the prior
written consent of the other which consent shall not be unreasonably withheld or
delayed, except that either party shall be entitled without the prior written
consent of the other to assign transfer, charge, subcontract, deal with or in
any other manner make over the benefit and/or burden of this Agreement to an
Affiliate, or to any limited liability partner or to any 50/50 joint venture
company of which the party in question is the beneficial owner of fifty percent
(50%) of the issued share capital thereof or to any company with which the party
in question may merge or to any company to which that party may transfer its
assets and undertakings.

         11.2 Publicity. The text of any press release or other communication to
be published by or in the media concerning the subject matter of this Agreement
shall require the prior written approval of ICOS and SGI.

         11.3 Notices. All notices, requests, demands, waivers, consents,
approval or other communications to any party hereunder shall be in writing and
shall be deemed to have been duly given if delivered personally to such party or
sent to such party by recorded electronic transmission (facsimile) or by
registered or certified mail, postage prepaid, to its address as shown below:

         SGI:          Seattle Genetics, Inc.
                       21823 30/th/ Drive S.E.
                       Bothell, WA  98021
                       Attention:  General Counsel

                                       14

<PAGE>

                                          [***] Confidential treatment requested

         ICOS:        ICOS Corporation
                      22021 20/th/ Avenue S.E.
                      Bothell, WA  98021
                      Attention:  Legal Department

or to such other address as the addressee may have specified in a notice duly
given to the sender as provided herein. Such notice, request, demand, waiver,
consent, approval or other communications will be deemed to have been given as
of the date so delivered, telegraphed, telexed, or five (5) days after so
mailed.

         11.4 Independent Contractor. Each party shall be and shall act as the
independent contractor of the other party. Neither party shall be the legal
agent of the other for any purpose whatsoever and therefore has no right or
authority to make or underwrite any promise, warranty or representation, to
execute any contract or otherwise to assume any obligation or responsibility in
the name of or on behalf of the other party, except to the extent specifically
authorized in writing by the other party. Neither of the parties hereto shall be
bound by or liable to any third persons for any act or for any obligation or
debt incurred by the other toward such third party, except to the extent
specifically agreed to in writing by the party so to be bound.

         11.5 Headings. All section headings and numbering contained in this
Agreement are for convenience of reference only, do not form a part of this
Agreement and shall not affect in any way the meaning or interpretation of this
Agreement.

         11.6 Entire Agreement. The Agreement, and the attached appendixes,
embodies the entire understanding of ICOS and SGI and there are no promises,
terms, conditions or obligations, oral or written, expressed on implied, other
than those contained in this Agreement, and the attached appendixes. The terms
of this Agreement shall supersede all previous agreements (if any) which may
exist or have existed between ICOS and SGI relating to the Services.

         11.7 Modifications. Any and all modifications or amendments to this
Agreement, or any Appendix hereto, shall be binding only if made in writing and
signed by both parties.

         11.8 Counterparts. This Agreement may be executed simultaneously in any
number of counterparts, each of which shall be deemed an original and all of
which together shall constitute one in the same agreement.

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date first above written.

ICOS CORPORATION                         SEATTLE GENETICS, INC.

By: /s/ Gary Wilcox                      By: /s/ Clay Siegall
   --------------------------------         ------------------------------------

Name: Gary Wilcox                        Name: Clay Siegall
     ------------------------------           ----------------------------------

Title: EVP, Operations                   Title: President & CEO
      -----------------------------            ---------------------------------

                                       15<PAGE>

                                                                    Exhibit 10.5

                              EMPLOYMENT AGREEMENT

     This AGREEMENT, effective April 30, 2001, is between ZymoGenetics, Inc., a
Washington corporation ("Company") and James A. Johnson ("Executive").

     1.   Employment. Company will employ Executive and Executive will accept
employment as Senior Vice President, Chief Financial Officer, of the Company.
Executive accepts employment upon the terms and conditions contained in this
Agreement and for the period (hereinafter called the "Term of Employment")
specified in Section 3 below.

     2.   Duties. Executive shall, during the Term of Employment, serve the
Company under the direction of the President of the Company. Executive shall
perform the duties of his position faithfully, diligently and competently and to
the best of his ability, and shall devote his full business time to his
employment. Executive shall perform such other duties as are assigned to him by
the President or the Board of Directors of the Company. Executive shall not
engage in any other business activity (except the management of personal
investments which in the aggregate do not interfere with the performance of
Executive's duties) without first obtaining the written consent of Company, such
consent not to be unreasonably withheld.

     3.   Term of Employment; Termination.

     Executive's Term of Employment shall be two years from the date of this
Agreement, unless extended or earlier terminated as provided below.

     (a)  Termination or Extension of Term of Employment By Company

     The Company shall employ Executive, for a period commencing on the date
hereof and terminating as follows:

          (i)  Two years from the date hereof, if at least thirty (30) days
prior to such date either the Company or Executive has, at its election,
notified the other in writing that this Agreement shall terminate on such date.
If notice of termination is not given, this Agreement shall be deemed to extend
from year to year. It can then be terminated by written notice at least thirty
(30) days prior to the annual renewal date.

          (ii) With or without "Cause" (as defined below), Company may terminate
the employment of Executive at any time upon giving "Notice of Termination" (as
defined below).

<PAGE>

     (b)  By Executive

     Executive may terminate his employment at any time, for any reason, upon
giving Notice of Termination.

     (c)  Automatic Termination

     This Agreement and Executive's employment hereunder shall terminate
automatically upon the death or total disability of Executive. The term "total
disability" as used herein shall mean Executive's inability to perform the
duties set forth in paragraph 1 hereof for a period or periods aggregating
ninety (90) calendar days in any 12-month period as a result of physical or
mental illness, loss of legal capacity or any other cause beyond Executive's
control, unless Executive is granted a leave of absence by the Board of
Directors of Company. Executive and Company hereby acknowledge that Executive's
ability to perform the duties specified in paragraph 2 hereof is of the essence
of this Agreement. Termination hereunder shall be deemed to be effective (a) at
the end of the calendar month in which Executive's death occurs or (b)
immediately upon a determination by the Board of Directors of Company of
Executive's total disability, as defined herein.

     (d)  Notice

     The term "Notice of Termination" shall mean at least thirty (30) days'
written notice of termination, by either party, of Executive's employment,
during which period Executive's employment and performance of services will
continue; provided, however, that Company may, upon notice to Executive and
without reducing Executive's compensation during such period, excuse Executive
from any or all of his duties during such period. Such a reduction in duties
shall not constitute "good reason" for voluntary termination so as to trigger
termination payments in accordance with subparagraph 4.2. The effective date of
the termination (the "Termination Date") of Executive's employment hiseunder
shall be the date on which such 30-day period expires.

     4.   Termination Payments

     In the event of termination of the employment of Executive, all
compensation and benefits set forth in this Agreement shall terminate except as
specifically provided in this paragraph 4:

     4.1  Termination by Company

     (a)  Upon termination by Company, Company shall pay Executive any unpaid
annual base salary which has accrued for services already performed as of the
Termination Date, plus any accrued, but unused, vacation.

                                       -2-

<PAGE>

     (b)  If Company terminates Executive's employment without Cause, as defined
below, Executive shall be entitled to receive termination payments equal to
twelve (12) months annual base salary and Company payments for Executive's
medical and dental insurance coverage under COBRA for a period of twelve (12)
months from the date of termination. The termination payments shall be
calculated according to Executive's base salary as of the date of Notice of
Termination and the termination payments will be paid semi-monthly in equal
parts in accordance with the same time schedule that Company or a "Successor
Company" (as defined in the Stock Option Agreement and incorporated by reference
herein) makes its customary payroll. Company or a Successor Company may deduct
customary withholdings including social security, federal and state income
taxes, and state disability insurance from these severance payments; however,
any and all such obligations shall be Executive's responsibility. Company will
issue and file appropriate Form 1099 or similar tax documents in connection with
any termination payments. The termination payments described in this paragraph
are expressly contingent upon Executive's full compliance with the terms of his
Employee Inventions and Proprietary Information Agreement with Company (the
"Inventions Agreement"), a copy of which is attached hereto. In the event
Executive were to materially breach this Inventions Agreement, his right to any
termination payments under this paragraph shall be extinguished, Company (and
any Successor Company) shall cease payments, and Executive shall immediately
return to Company or to any Successor Company any severance payments already
made. If Executive is terminated by either Company or any Successor Company for
Cause, Executive shall not be entitled to receive any of the foregoing benefits,
other than those set forth in clause (a) above.

     4.2  Termination by Executive

     In the case of the termination of Executive's employment by Executive for
"good reason," as defined below, Executive shall be entitled to the termination
payments as set forth in clauses 4.1(a) and (b). In the case of termination of
Executive's employment by Executive for any other reason, Executive shall not be
entitled to any termination payments or accelerated vesting benefit, other than
as set forth in clause 4.1(a), above.

     4.3  Termination as a Result of Death or Total Disability

     In the event of termination of Executive's employment pursuant to
subparagraph 3(c), Executive or his estate shall be paid the compensation set
forth in clause 4.1(a) and shall not be entitled to any of the benefits under
clauses 4.1(b).

                                      -3-

<PAGE>

     4.4  "Good Reason"

     "Good reason" shall mean the occurrence of any of the following events,
without the consent of the Executive:

     a) a demotion or other material reduction in the nature or status of
        Executive's responsibilities; provided, however, that a change in the
        person or office to which Executive reports, without a corresponding
        reduction in duties, status and responsibilities, shall not constitute
        "good reason;"

     b) a non-voluntary reduction in the Executive's annual base salary;

     c) requirement by a Successor Company that the Executive relocate his
        principal place of employment to a location that is more than 50 miles
        from the principal place of employment where Executive was employed; or

     d) the failure of Company to obtain a satisfactory agreement from any
        Successor Company to assume and perform the obligations under this
        Agreement.

     4.5  Cause

     Wherever reference is made in this Agreement to termination being with or
without Cause, "Cause" shall include, without limitation, the occurrence of one
or more of the following events:

     a) willful misconduct, insubordination, or dishonesty in the performance of
        Executive's duties or other knowing and material violation of Company's
        or a Successor Company's policies and procedures in effect from time to
        time which results in a material adverse effect on Company or a
        Successor Company;

     b) willful actions (or intentional failures to act) in bad faith by
        Executive with respect to Company or a Successor Company that materially
        impair Company's or a Successor Company's business, goodwill or
        reputation;

     c) conviction of Executive of a felony involving an act of dishonesty,
        moral turpitude, deceit or fraud, or the commission of acts that could
        reasonably be expected to result in such a conviction; or

     d) any material violation by Executive of Executive's Inventions Agreement
        with Company.

                                       -4-

<PAGE>

     5.   Compensation and Fringe Benefits.

     (a)  The Company shall, during the Term of Employment, pay to the Executive
as compensation for the performance of his duties and obligations a salary of
$240,000 per annum. This compensation is subject to annual review and
adjustment, as appropriate in the judgment of the Company. The compensation
payable pursuant to this Section 5(a) shall be payable in equal semi-monthly
installments on the last day of each such pay period.

     (b) The Executive shall be enrolled and participate in any retirement,
group insurance and other fringe benefit plans and arrangements which are
applicable to the similarly situated personnel of the Company and in effect from
time to time, if the Executive is eligible therefor, in each case in accordance
with and subject to the provisions thereof.

     (c)  Stock Options

          (i)   Executive has been granted a ten-year stock option under the
Company's Amended and Restated 2000 Stock Incentive Plan, dated August 23, 2000,
which allows Executive to purchase 80,000 shares of the Company's common stock.

          (ii)  Executive shall be eligible to receive future periodic (i.e.,
non bonus-related) grants under the Company's stock incentive programs.

     (d)  Executive will also receive the following executive perquisites for
the duration of this contract:

          (i)   Company-paid term life insurance policy in the amount of
$200,000; and

          (ii)  Company-paid use of either a laptop computer or personal
computer, to be upgraded bi-annually at the time this contract is renewed; and

          (iii) Company-paid annual executive health physical, to be
administered by a physician selected by the Company; and

          (iv)  Company-paid expenses for a residential phone and cellular
phone.

     (e)  Upon the effective date of the Company's initial public offering,
Executive shall earn a bonus, before taxes, of $50,000, to be paid by the
Company as soon as practicable after such effective date. If Executive remains
continuously and regularly employed with the Company (i.e., his employment has
not been terminated, whether voluntarily or involuntarily) through the period
ending one year from the

                                       -5-

<PAGE>

effective date of the Company's initial public offering, the Company shall pay
Executive an additional bonus, before taxes, of $50,000, within ten (10) days
after the end of such period.

     6.   Expenses. All travel and other reasonable expenses incident to the
rendering of service by the Executive hereunder will be paid by the Company. If
such expenses are paid in the first instance by the Executive, the Company will
reimburse him upon presentation of proper expense accounts. Reimbursement
requests, along with supporting documentation, should be submitted within sixty
(60) days of incurring the expense.

     7.   Non-competition.

     (a)  Upon termination of Executive's employment with the Company for any
reason, and for a period of twelve (12) consecutive months after leaving his
employment with the Company, Executive will not directly or indirectly work or
otherwise engage in research, manufacture, sale or distribution of any product,
method or matter:

          (i)   For any business, whose commercial efforts are in competition
with the products manufactured or marketed by the Company during Executive's
employment with the Company or under research or development by the Company
during Executive's employment with the Company (and on which the Company has
expended at least $1,000,000); or

          (ii)  For any research institution whose research efforts pertain to
the same products manufactured or marketed by the Company during Executive's
employment with the Company or under research or development by the Company
during Executive's employment with the Company (and on which the Company has
expended at least $1,000,000), unless the Executive is not involved in any
manner in the design, conduct or supervision of such research efforts, or unless
such research is being conducted solely for scientific and not for commercial
purposes. The executive shall be deemed to be connected with a business if such
business is carried on by partnership in which he is a general or limited
partner, consultant or employee, or a corporation or association of which he is
a shareholder, officer, director, employee, member, consultant or agent;
provided, that nothing herein shall prevent the purchase or ownership by the
Executive of shares of less than 1% of the outstanding shares in a publicly or
privately held corporation.

                                      -6-

<PAGE>

     Said twelve (12) months' period shall commence on the day on which the
Executive actually leaves his employment with the Company, even if this date is
prior to the expiration of any given notice of termination.

     (b)  The Company's Board of Directors may, at its own discretion, by
express or written consent, release the Executive from the restriction in
paragraph 6(a).

     (c)  For a period of one (1) year after the employment of the Executive is
terminated for any reason, Executive will not directly or indirectly, either for
Executive's account or as representative or agent for any other person, firm,
corporation or entity, solicit the services of, or entice away, any executive of
the Company, or the executive of any company affiliated with the Company.

     (d)  In the event that Executive during said period described in paragraph
6(a) violates any of the Executive's obligations towards the Company, including
but not limited to the Executive accepting a position with a competing
enterprise or Executive violating terms of paragraph 6(c), payment of Severance
or Salary Continuation shall cease automatically without notice, regardless of
whether the Company takes legal action or otherwise tries to enforce its rights.
The Company reserves all rights it may have under contract or law to relief or
damages in addition to termination of the above-described payments.

     8.   Binding Effect. This Agreement shall be binding upon and inure to the
benefit of the Company and the Executive and their respective heirs, legal or
personal representatives, successors and assigns.

     9.   Rights of Assignment or Delegation. This Agreement is personal to the
Executive and shall not be assignable. Company may assign its rights hereunder
to (a) any corporation resulting from any merger, consolidation, or other
reorganization to which Company is a party or (b) any corporation, partnership,
association, or other person to which Company may transfer all or substantially
all of the assets in business of Company existing at such time. All the terms
and provisions of this Agreement shall be binding upon and shall inure to the
benefit and be enforceable by the parties hereto and their respective successors
and permitted assigns.

     10.  Waiver. No delay or failure by any party in exercising, protecting or
enforcing any of its rights, titles, interests, or remedies hereunder and no
course of dealing or performance with respect thereto, shall constitute a
waiver. The express waiver by a party of any right, title, interest, or remedy
in a particular instance or circumstance shall not constitute a waiver in any
other instance or circumstance. All rights and remedies shall be cumulative and
not exclusive or any rights or remedies.

                                       -7-

<PAGE>

     11.  Arbitration. Any controversies or claims arising out of or relating to
this Agreement shall be finally and fully settled by arbitration in the City of
Seattle, Washington in accordance with the Employment Arbitration Rules of the
American Arbitration Association then in effect (the "AAA Rules"), conducted by
one arbitrator, mutually agreed upon by Company and Executive or chosen in
accordance with the AAA Rules, except the parties thereto shall have any right
to discovery that would be permitted by the Federal Rules of Civil Procedure for
a period of 90 days following the commencement of such arbitration and the
arbitrator shall resolve any dispute which arises in connection with such
discovery. The prevailing parties shall be entitled to costs, expenses,
reasonable attorneys' fees, and judgment upon the award rendered by the
arbitrator. The award may be entered in any court having jurisdiction.

     12.  Amendments in Writing. No amendment, modification, waiver, termination
or discharge of any provision of this Agreement, nor consent to any departure by
either party, shall in any event be effective unless the same shall be in
writing, specifically identifying this Agreement and the provision intended to
be amended, modified, waived, terminated, or discharged and assigned by Company
and Executive. Each such amendment, modification, waiver, termination, or
discharge shall be effective only in the specific instance and for the specific
purpose for which given. No provision of this Agreement shall be varied,
contradicted, or explained by any oral agreement, course of dealing or
performance or any other matter not set forth in agreement in writing and signed
by Company and Executive.

     13.  Notices. Any notice required or desired to be given hereunder shall be
in writing and shall be deemed sufficiently given when delivered or when mailed
by first class certified or registered mail, postage prepaid, to the party for
whom intended at the following address:

     To the Company:

                Dr. Bruce L. A. Carter
                CEO and President
                ZymoGenetics, Inc.
                1201 Eastlake Avenue East
                Seattle, WA 98102

     To the Executive:

                James A. Johnson
                Senior Vice President, Chief Financial Officer
                8503 Inverness Drive N.E.
                Seattle, WA 98115

or to such other address, as to either party, as such party shall from time to
time designate by like notice to the other.

                                       -8-

<PAGE>

     14.  Entire Agreement. This Agreement will, upon the commencement of the
Term of Employment, supersede all prior agreements between the Executive and the
Company, except the Employee Inventions and Proprietary Information Agreement
dated February 1, 2001, and any such prior agreements and the terms and
conditions thereof shall hereafter be null, void and of no effect.

     15.  Governing Law. This Agreement is made under and shall be governed by
and construed in accordance with the internal laws of the State of Washington.

     16.  Severability. If any provision of this Agreement shall be held
invalid, illegal or unenforceable in any jurisdiction, for any reason, including
without limitation, the duration of such provision, it's geographical scope or
the extent of the activities prohibited or required by it, then, to the full
extent permitted by law (a) all other provisions hereof shall remain in full
force and effect and such jurisdiction shall be liberally construed in order to
carry out the intent of the parties as nearly as may be possible, (b) such
invalidity, illegality, or unenforcability shall not effect the validity,
legality or enforceability of any other provision, and (c) any court or
arbitrator having jurisdiction there over shall have the power to reform such
provision to the extent necessary for such provision to be enforceable under
applicable law.

     17.  Multiple Copies. This Agreement may be executed in two or more
counterparts of like tenor and effect, each of which shall be deemed an original
but all of which together shall constitute one and the same instrument.

                                    ZYMOGENETICS, INC.

                                    By: /s/ Bruce L.a. Carter
                                        --------------------------------------
                                    Dr. Bruce L. A. Carter, President and CEO

                                    EXECUTIVE:

                                     /s/ James A. Johnson
                                    ------------------------------------------
                                    James A. Johnson

                                       -9-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}]]